提高投资者回报 研发管线潜在价值凸显 根据公司业绩快报，公司全年实现基本每股收益0.74元，同比增长15.63%，实现企业对投资者回报的提 高。 本报讯 （记者袁传玺）天士力2025年加入华润体系后首年融合业绩超出市场预期。2月6日晚间，天士 力发布的2025年业绩快报显示，公司2025年实现营业总收入82.36亿元；实现归属于上市公司股东的净 利润11.05亿元，同比增加15.68%。 融入华润体系推动提质增效 据悉，天士力作为华润三九"一体两翼"战略中的"一翼"，核心定位为"创新驱动"。天士力正全面推进与 华润三九的首年融合工作，从"价值重塑"、"业务重塑"、"组织重塑"和"精神重塑"四个维度系统化升级 管理体系，实现强强联合的战略协同。 公司在融入华润体系的同时，进行组织和运营管理等各个方面的优化，逐步提升公司经营资产的质量。 申万宏源证券的研报指出，华润三九将借助其在管理、渠道、产业方面的资源，为公司进一步赋能，促 进协同效应，提升天士力的竞争优势。在运营管理方面，公司积极落实华润管理理念，加强财务、人力 资源、EHSQ及大监督体系的融合，开展"焕新增效"等系列组织优化活动，优化运营管控模式，提升管 ...

Core Viewpoint - The recent surge in the stock price of Zhen Dong Pharmaceutical is attributed to significant advancements in innovative drug development, product pipeline implementation, and corporate governance optimization, which are gaining recognition in the capital market [1][4]. Group 1: Innovative Drug Development - Zhen Dong Pharmaceutical's subsidiary, Zhen Dong Anxin Biotech, received formal acceptance from the National Medical Products Administration for its finasteride tablet generic drug application, targeting common conditions such as androgenetic alopecia and benign prostatic hyperplasia, enhancing the company's position in the hair health sector [1]. - The company achieved a milestone in gynecological innovative drugs with the acceptance of its new drug application for a vaginal probiotic capsule, which utilizes an innovative mechanism to restore vaginal microecology, showing superior cure rates and safety compared to traditional antibiotics [2]. - Ongoing research in oncology includes projects for gastric cancer (ZD09), breast cancer bone metastasis (ZDH02), and atopic dermatitis (SH003), alongside a newly introduced epinephrine nasal spray for out-of-hospital intervention in allergic shock, which has secured core patents in Europe and the US [2]. Group 2: Consumer Health and Brand Development - Zhen Dong Pharmaceutical is actively promoting its "Dafeixin" brand through social media platforms and partnerships with chain pharmacies, achieving a 31.34% year-on-year increase in net profit to 12.43 million yuan in Q3 2025, reflecting the profitability of its high-value products [3]. - The company has also received approval for the "Dafeixin" cypress leaf anti-hair loss shampoo, further expanding its product matrix in hair health [3]. Group 3: Corporate Governance and Structural Improvements - The company is enhancing its governance by implementing cumulative voting in board elections to protect minority shareholders' rights and improve decision-making processes [3]. - Recent share purchases by board member Lei Zhenhong demonstrate confidence in the company's long-term value, with an acquisition of 1,600 shares at an average price of 5.99 yuan per share [3]. Group 4: Strategic Transformation - Zhen Dong Pharmaceutical is transitioning from a traditional "generic + Chinese herbal medicine" model to a dual-engine strategy focused on "innovative drugs + consumer health," laying a solid foundation for long-term development and high-quality growth [4].

证券日报网2月6日讯 ，福元医药在接受调研者提问时表示，公司创新药的研发立项思路是以市场价值 为导向，聚焦尚未满足的临床需求，进行差异化立项，并切合公司管线及成熟的销售优势。小核酸是继 小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。公司的 N-ER平台是以福元医药自主研发为技术基础的创新核酸药物发现及递送系统的研发平台。公司已搭建 创新核酸药物设计、合成、修饰、生物学评价、药学研究一体化研发平台。截至目前进展最快的管线在 进行I期临床实验。 （文章来源：证券日报） ...

Core Viewpoint - CITIC Securities has issued a "buy" rating for Baile Tianheng, setting a target price of no more than 1322 yuan, predicting a net profit of -760 million yuan for 2025 [1] Group 1: Financial Performance - As of the report's release, Baile Tianheng's A-share price was 282.30 yuan per share, having increased over tenfold since its listing two years ago [1] - The predicted price implies a potential increase of over 468%, with a market capitalization exceeding 546 billion yuan if the target price is reached [1] - However, four days later, Baile Tianheng announced an earnings forecast indicating a net profit of approximately -1.1 billion yuan for 2025, a year-on-year decline of about 129.67%, significantly worse than CITIC Securities' forecast [3] - The expected revenue for 2025 is around 2.5 billion yuan, reflecting a year-on-year decrease of approximately 57.06% [3] - Historical performance shows Baile Tianheng's net profit fluctuating dramatically, with figures of -100 million yuan, -282 million yuan, -781 million yuan, and 3.708 billion yuan from 2021 to 2024 [5] Group 2: Research and Development - Baile Tianheng has increased its R&D investment to accelerate product pipeline development, which has led to a significant rise in R&D expenses [3] - The company has 17 innovative drugs in clinical trials, with 6 in global trials, and is conducting over 100 clinical trials worldwide [7] - The core product Iza-bren has received priority review status from the National Medical Products Administration (NMPA) for new indications, which is a key reason for CITIC Securities' positive outlook [4] Group 3: Strategic Partnerships - Baile Tianheng's collaboration with Bristol-Myers Squibb (BMS) on Iza-bren is progressing well, achieving a milestone in the global II/III phase key registration clinical trial, resulting in a milestone payment of 250 million USD [3] - The previous year, the company received an irrevocable and non-deductible upfront payment of 800 million USD from BMS, which contributed to higher income recognition in the prior period compared to the current period [3]

"十五五"规划下，医药领域的国家队企业备受资本市场关注。天士力2025年加入华润体系后成为华润三 九"一体两翼"战略中的"一翼"，首年融合业绩超出市场预期。公司近日发布2025年全年业绩预告称，预 计实现归母净利润11.05亿元，同比增加15.68%。 据公司此前披露，在百日融合期内公司与华润三九协同赋能，在营销领域整合线上线下渠道资源，创新 医药零售新模式。在营销领域积极与华润进行融合赋能，并加强与华润医商"新产品"合作，建立新品目 标终端开发协同机制。在渠道拓展方面，与华润三九健康消费品（CHC）业务开展了充分协同。借助 华润三九药品零售连锁（KA）平台，公司与头部连锁药店深化战略合作关系，并选取代表性产品入驻 三九旗舰店，与华润三九在产品打造、数据共享等各方面开展了深入合作。 信达证券近期研报指出，华润三九是国内健康消费品领域的龙头，具备行业领先的渠道资源和品牌能 力，作为华润系央企，同时具备富有远见的战略规划和市场化的经营思路，目前双方融合顺利推进，有 望给天士力带来积极变革。申万宏源证券的研报也指出，期待华润三九将借助其在管理、渠道、产业方 面的资源，为公司进一步赋能，促进协同效应，提升天士力的竞争 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected stock price increase of over 15% in the next six months [3]. Core Insights - The company is advancing its innovative pipeline, with a focus on expanding its cancer treatment portfolio. The recent approval of SYS6090 for clinical trials highlights its potential in treating advanced lung cancer [1][2]. - SYS6090 is a recombinant fully human anti-PD-1 antibody fused with IL-15, showing significant efficacy and safety in preclinical studies, outperforming other PD-1 monoclonal antibodies [1]. - The company has a rich pipeline with multiple drugs in critical clinical trial phases, including SYS6010 and DP303c, which have demonstrated promising results in their respective trials [2]. Financial Summary - The company’s revenue is projected to decline from 2,539 million in 2023 to 1,981 million in 2024, before recovering to 2,970 million by 2027, reflecting a compound annual growth rate (CAGR) of approximately 14.67% from 2025 to 2027 [4]. - The net profit attributable to the parent company is expected to recover significantly from 54 million in 2024 to 246 million in 2027, with an EPS increase from 0.04 to 0.18 during the same period [4]. - The company’s market valuation is projected to decrease from a PE ratio of 967 in 2025 to 212 in 2027, indicating an improving profitability outlook [4].

近日，上海生生医药冷链科技股份有限公司（下称"上海生生"）向港交所提交招股书。此前，公司曾递 表科创板，但最终无果而终。根据弗若斯特沙利文的报告，按2024年收入计，上海生生是中国市场排名 第一的制药及生命科学温控供应链服务提供商。在临床试验温控供应链这一细分领域，公司客户覆盖了 中国前20大制药公司的100%，以及全球前20大制药公司的50%。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：天利 作为中国排名第一的制药及生命科学温控供应链服务商，上海生生身处创新药研发的黄金赛道，"卖水 人"故事颇具吸引力。但同时，对招股书等相关资料进行后发现，公司目前仍存在诸多隐忧，包括营收 增长停滞、业务结构高度集中、关联交易错综复杂以及实控人资本运作颇具争议等。 营收"止步不前"增长瓶颈隐现 毛利率走高背后财务真实性或存疑 从财务数据看，上海生生近年营收稳健增长，2023年、2024年及2025年前三季度分别为6.14亿元、6.54 亿元、5.38亿元。但将时间线拉长看，早在2021年，上海生生的收入就已经达到5.25亿元，2022年为 6.34亿元。由此 ...

Core Viewpoint - Federal Pharmaceutical (03933) has seen a significant stock increase, attributed to the announcement of its innovative drug UBT251 receiving clinical trial approval for obesity-related moderate to severe obstructive sleep apnea (OSA) from the National Medical Products Administration of China [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has developed UBT251, which is the first chemical-synthetic GLP-1/GIP/GCG tri-target receptor agonist new drug in China [1] - The company has established a strong position in the research field of this type of medication, enhancing its competitive edge [1] Group 2: Financial Insights - UBS has released a report stating that Federal Pharmaceutical is a leading drug manufacturer in China, with an integrated business line covering intermediate products, active pharmaceutical ingredients, and formulation products [1] - The company has a strong research and development background in metabolic diseases, which has led to promising early clinical results for UBT251 [1] - In March of the previous year, the company licensed the rights for UBT251 outside of China to Novo Nordisk (NVO.US), which included a $200 million upfront payment, up to $1.8 billion in milestone payments, and tiered royalties on sales [1] Group 3: Market Potential - UBS believes that the market has underestimated the sales potential of UBT251 and the broader innovative research and development pipeline of the company [1]

Core Viewpoint - Federal Pharmaceutical (03933) has seen a significant stock increase of over 7%, currently trading at HKD 13.39, with a transaction volume of HKD 80.98 million, following the announcement of its innovative drug UBT251 receiving clinical trial approval for obesity-related moderate to severe obstructive sleep apnea (OSA) from the National Medical Products Administration of China [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has independently developed the innovative drug UBT251 injection, marking it as China's first chemical-synthesized GLP-1/GIP/GCG tri-target receptor agonist [1] - The company has established a significant position in the research field of this type of medication, enhancing its competitive edge in the pharmaceutical industry [1] Group 2: Market Analysis - UBS has released a report stating that Federal Pharmaceutical is a leading drug manufacturer in China, with an integrated business line that includes intermediate products, active pharmaceutical ingredients, and formulation products [1] - The report highlights that the market may be underestimating the sales potential of UBT251 and the broader innovative research pipeline of the company [1] - Last year, the company licensed the rights of UBT251 outside of China to Novo Nordisk (NVO.US), which included an upfront payment of USD 200 million, potential milestone payments of up to USD 1.8 billion, and tiered royalties on sales [1]

春回大地，万象启新！2026年2月4日，恰逢立春时节。在国家1类新药琥珀八氢氨吖啶片获批进入倒计时的关键节点，为深化推进集团创新转型，加速集 团北京总部暨北京科创中心的战略落地，大兴区委书记初军威、区长刘洋、副区长安学军等区领导隆重会见金马药业集团董事长张玉富先生一行。 区委书记初军威介绍大兴区产业布局，区长刘洋，副区长安学军陪同参观 双方以春为约，围绕创新药获批后的总部建设、科创中心落地、新药生产及商业化推广、神经领域创新药持续投入和研发、智能医疗生态构建等核心议题 深度磋商，达成全方位共识，为金马药业扎根"中国药谷"、赋能首都医药健康产业高质量发展注入磅礴动能，让合作共赢的信心与春天的朝气一同升腾！ 集团医疗板块总裁、建设板块总裁，研发副总裁、金融副总裁、IT总监陪同调研。 参观北京市大兴区营商服务中心 行程伊始，在区委书记初军威、区长刘洋、副区长安学军等区领导的全程陪同下，集团项目工作组走进大兴区营商服务中心。 初军威书记亲自推介区域发展优势：大兴区立足首都都市圈核心枢纽定位，坐拥临空经济区、自贸区、综保区"三区叠加"的独特政策红利，联动京津冀协 同发展的战略价值凸显。全区锚定生命健康、临空产业、先进制 ...